Phase 2A Multi-Centre, Double Blind, Placebo Controlled 3-Way Cross-Over Study To Investigate The Effect Of Single Doses Of PF-00446687 On Sexual Arousal And Sexual Desire In Women Suffering From Female Sexual Dysfunction (FSD).
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2013
At a glance
- Drugs PF 446687 (Primary)
- Indications Female sexual dysfunction
- Focus Therapeutic Use
- Sponsors Pfizer
- 24 Mar 2012 Planned number of patients changed from 23 to 24 as reported by European Clinical Trials Database record.
- 06 Jun 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.
- 23 Oct 2007 New trial centres added.